X

Global Hepatic Encephalopathy Market to Register a CAGR of 5.4% over the Forecast Period

The Global Hepatic Encephalopathy Market size is anticipated to grow at a CAGR of 5.4% over the forecast period. Hepatic encephalopathy (HE) is a disorder usually detected in patients suffering from cirrhosis. In all those with acute liver failure and those with cirrhosis associated with end stage liver disease, HE is a symptom of poor prognosis, and it is associated with considerably high mortality. Liver cirrhosis is a gastroenterological disease characterized by gradual, progressive, and permanent fibrous tissue (scar) replacement of liver cells that prevents proper functioning of the liver.

Generally, liver cirrhosis affects up to 1 percent of the U.S. and EU population, according to the National Center for Biotechnology Information (NCBI): 2014. Due to HE related complications, between 180,000 and 290,000 patients with cirrhosis in the US are hospitalized every year. Once hepatic encephalopathy develops, after five years, mortality reaches 22-35%.

Increased hospitalization and care bills are also correlated with HE. In addition, in about 70 percent of cirrhosis cases, slight symptoms of HE are found. For the prevention of hepatic encephalopathy, multiple forms of experimental medications are in the pipeline. The growth of the global hepatic encephalopathy market is being driven by the rising cases of HE. Further, the  market growth is also expected to be powered by a growing number of products in the pipeline for HE care.

Hepatic Encephalopathy Market, By Drug

Based on drugs, the hepatic encephalopathy market is categorized into antibiotic, laxatives, and others. In order to delay the growth of bacteria in the intestine, including bacteria that contain ammonia, antibiotics such as Rifaximin and Metronidazole can be used. This is expected to support the growth of the antibiotic segment over the next few years.

Hepatic Encephalopathy Market, By Type

Based on type, the global market has been segmented into type A, type B, and type C. Type C is the most common hepatic encephalopathy seen in patients with cirrhosis or advanced fibrosis. Hepatic encephalopathy type C is mainly associated with cirrhosis. When destructive fibrosis matures, cirrhosis is the last step of progressive liver disease. Increasing prevalence of cirrhosis is expected to drive the growth of the type C segment.

Hepatic Encephalopathy Market, By Distribution Channel

Based on the distribution channel, the hepatic encephalopathy market is categorized into hospitals, retail, and online channels. The hospital segment is going to dominate the market during the forecast period. Increasing investment in healthcare and drug development, increasing prevalence of diseases, and growing patient pool are the main factors that are expected to propel the growth of the hospital segment over other segments.

Hepatic Encephalopathy Market, By Treatment

Based on treatments, the hepatic encephalopathy market is categorized into lactulose, antibiotics, probiotics, branched-chain amino acids, and liver transplantation. Lactulose is a synthetic form of sugar that is not absorbed into the body. Lactulose is also used in people with liver disease to decrease the level of ammonia in their blood. By extracting ammonia from the blood into the colon, from where ammonia is eliminated from the body. The increasing usage of lactulose for the treatment of HE will augment the growth of this segment.

Hepatic Encephalopathy Market, By Regions

In the worldwide hepatic encephalopathy industry, North America is holding a leading position. The domination of the region is due to the growing consumer awareness about multiple care choices and increasing demand for treatment. Due to increasing population and rising demand for fast diagnosis globally, the market for hepatic encephalopathy is expected to grow in this region.

Key Developments in the Hepatic Encephalopathy Market

  • Umecrine Cognition, a pharmaceutical firm based in Sweden, is actively designing a treatment that represents a new target class for various CNS-related disorders. Currently in clinical research for HE, the lead compound is GR3027. The business plans to show GR3027's Phase II results for HE care in 2020.
  • Rebiotix Inc. is developing the drug RBX2477, which can be delivered orally. The medicine is currently being scientifically tested in Phase I. It is an antibiotic that decreases ammonia development by constraining the growth of colonic bacteria that contain ammonia.
  • In August 2019, Mallinckrodt announced the beginning of the Phase IIa clinical trial study for MNK-6106 (L-ornithine phenylacetate) versus rifaximin.

Some Key Findings of the Hepatic Encephalopathy Market Report Include:

  • The analysis includes the global hepatic encephalopathy market study, expansions, and forecasts, along with a country-specific analysis.
  • An in-depth analysis of the global hepatic encephalopathy market comprises segment by drug, by type, by treatment, and by regions with an analysis of trend-based insights and factors.
  • Product offering details on competitive benchmarking and evolution approach adopted by the industry players, along with their investments in the last five years in the global market have also been provided in the study.
  • The market research includes a study of the provinces, boundaries, drivers, prospects, guidelines, challenges, and procedures that are propelling the global hepatic encephalopathy market.
  • The study also offers complex measures of potential market effect during the forecast period and provides an in-depth overview of the leading companies operating in the market.
  • External as well as internal variables that are expected to have a positive or negative effect on companies have been evaluated, which will offer the decision makers a strong futuristic view of the industry.
  • The research includes the dynamics of the hepatic encephalopathy market structure by analyzing market segments of the hepatic encephalopathy market.
  • Some major industry players functional in the global hepatic encephalopathy market include Alfa Wassermann S.p.A, Cosmo Pharmaceuticals S.p.A, KannaLife Sciences, Inc., Ocera Therapeutics, Inc., Rebiotix Inc., Spherium Biomed S.L., and Umecrine Cognition AB, among others.

Market Segmentation

By Drug

  • Antibiotic
  • Laxatives
  • Others

By Type

  • Type A
  • Type B
  • Type C

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Channels

By Treatment

  • Lactulose
  • Antibiotics
  • Probiotics
  • Branched-chain Amino Acids
  • Liver Transplantation

By Region:

  • North America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East
  • Rest of the world
Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision

Recommendations

Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements